title: Complexation With Human Serum Albumin Facilitates Sustained Release of Morin From Polylactic-Co-Glycolic Acid Nanoparticles.
abstract: Understanding the interaction of proteins with nanoparticles has become an important area of research in biomedical and pharmaceutical fields. Morin is a flavonol which shows several properties including antioxidant, anticancer, and anti-inflammatory activities. However, the major limitation is its poor aqueous solubility. Therefore, morin-loaded polylactic-co-glycolic acid (PLGA) nanoparticles (MPNPs) were prepared to improve the solubility of morin. The resulting MPNPs were characterized by spectroscopic and microscopic techniques. The nanoparticles were spherical with an average size of 237 ± 17 nm. UV-visible, fluorescence, and circular dichroism (CD) spectroscopy were employed to study the interaction of the MPNPs with human serum albumin (HSA). Our study revealed that a static fluorescence quenching mechanism was involved in the interaction between HSA and MPNPs. Hydrophobic interactions also play an important role in stabilizing the HSA-MPNP complex. CD results suggest that there is an alteration of the secondary structure of HSA in the presence of MPNPs. MPNPs exhibit antioxidant properties which are supported by the DPPH assay. We have further checked the effect of HSA on the antioxidant property of morin and MPNPs. HSA binding with MPNPs was also found to influence the in vitro release property of morin from MPNPs wherein a delayed release response is observed.
authors.affiliation: Department of Chemistry, Indian Institute of Technology Kharagpur , Kharagpur 721302, India.
authors.forename: Pooja
authors.initials: P
authors.lastname: Ghosh
authors.affiliation: Department of Chemistry, Indian Institute of Technology Kharagpur , Kharagpur 721302, India.
authors.forename: Jayita
authors.initials: J
authors.lastname: Patwari
authors.affiliation: Department of Chemistry, Indian Institute of Technology Kharagpur , Kharagpur 721302, India.
authors.forename: Swagata
authors.identifier: 0000-0003-2074-1247
authors.initials: S
authors.lastname: Dasgupta
mesh_terms: D000975:Antioxidants / Q000008:administration & dosage* / Q000494:pharmacology; D001713:Biphenyl Compounds / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000737:chemistry*; D005419:Flavonoids / Q000008:administration & dosage* / Q000494:pharmacology; D005609:Free Radicals / Q000737:chemistry; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D019344:Lactic Acid / Q000737:chemistry*; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D010316:Particle Size; D010851:Picrates / Q000737:chemistry; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D000075462:Serum Albumin, Human / Q000737:chemistry*; D047309:Flavones
chemical_list: D000975:Antioxidants; D001713:Biphenyl Compounds; D003692:Delayed-Action Preparations; D005419:Flavonoids; D005609:Free Radicals; D019344:Lactic Acid; D010851:Picrates; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D000075462:Serum Albumin, Human; C008548:morin; D047309:Flavones; C004931:1,1-diphenyl-2-picrylhydrazyl